摘要
肾细胞癌(renal cellcarcinoma,RCC)是泌尿系统常见的肿瘤之一,且发病率逐年上升。目前诊断RCC缺乏特异性的肿瘤标志物。由于RCC对放疗、化疗和免疫治疗的耐受性差且效果不佳,外科手术仍然是RCC主要的治疗方法。长链非编码RNA(Long non-coding RNA,LncRNA)是分子量大于200个核苷酸的不具有编码蛋白质功能的非编码RNA,近年来发现LncRNA可作为肾癌标志物且具有诊断价值,此外在肿瘤的发生和进展等方面显示出良好的研究潜力,为肾癌诊断、治疗提供了一种新思路。本文重点就LncRNA在RCC的诊断、治疗和预后等方面的研究进展做一综述。
Renal cell carcinoma(RCC)is one of the common tumors of the urinary system,the incidence of which is increasing year by year.Currently,there is no specific tumor marker for diagnosis of RCC.Surgery is still the most effective treatment for RCC due to its tolerance to radiotherapy,chemotherapy and immunotherapy.Long non-coding RNA(LncRNA)is a non-coding RNA with molec⁃ular weight more than 200 nucleotides which doesn’t encode protein.Recently found that LncRNA could be used as a marker of renal cancer and showed promising value in neogenesis,progression and diagnosis of tumors,which provides a new inspiration for diagnosis and treatment of RCC.This review focused on the research progress of LncRNA in diagnosis,treatment and prognosis of RCC.
作者
程波
邹菊
向碧兰
王倩
刘威
叶涛
CHENG Bo;ZOU ju;XIANG Bilan;WANG Qian;LIU Wei;YE Tao(Department of Urology,the Affiliated Hospital of S.M.U,Luzhou 646000,China;Clinical School of Medicine,Southwest Medical University.M.U,Luzhou 646000,China)
出处
《西南医科大学学报》
2022年第3期272-276,共5页
Journal of Southwest Medical University
基金
国家级大学生创新创业项目(202110632010)
西南医科大学应用基础研究青年项目(2021ZKQN071)。
关键词
肾细胞癌
长链非编码RNA
诊断
治疗
预后
Renal cell carcinoma
Long non-coding RNA
Diagnosis
Treatment
Prognosis
作者简介
第一作者:程波,主治医师,博士后。E-mail:cb1949@163.com。
